Mass Spectrometry Contribution to Pediatric Cancers Research

Area of Science:

• Proteomics
• Cancer Research
• Epigenetics

Background:

• Mass spectrometry (MS) has been instrumental in cancer research for over 40 years.
• Biomarkers identified through MS aid in therapy monitoring, cancer subtyping, and complementing genomic data.
• Epigenetics is increasingly recognized as a key factor in carcinogenesis.

Purpose of the Study:

• To highlight the contribution of mass spectrometry-based proteomics to cancer biomarker discovery.
• To discuss the role of proteomics in understanding cancer initiation and progression.
• To review recent investigations, including those using MS and 2D gel electrophoresis.

Main Methods:

• Mass spectrometry-based proteomics for biomarker identification and validation.
• High-resolution mass spectrometry for systematic quantification of chromatin modifications.
• Two-dimensional gel electrophoresis combined with mass spectrometry.

Main Results:

• MS-based proteomics provides essential proteomic data for cancer research.
• Systematic quantification of chromatin modifications using high-resolution MS is a recent advancement.
• Proteomic data aids in identifying targeted therapies and understanding drug resistance.

Conclusions:

• Mass spectrometry-based proteomics is an invaluable tool in cancer research.
• Understanding epigenetic modifications through MS is critical for developing new cancer therapies.
• Continued investigation using MS-based proteomics will advance cancer treatment strategies.